MP0310 is the first product candidate in our DARPin immuno-oncology pipeline. It is designed to activate immune cells specifically in the tumor and not in the rest of the body, potentially delivering greater efficacy with fewer side effects.
While checkpoint antibodies have delivered strong clinical results, immune agonistic antibodies have been either too toxic or not efficacious, with no good therapeutic window.
An immunotherapy that would solely activate immune cells in the tumor would allow super-activation while avoiding systemic side effects.
MP0310 comprises localizer (FAP) and stimulator (4-1BB) DARPin domains. Immune cells are activated only when both simultaneously engage with their targets, leading to tumor localized activity.